Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
前收盤價
US$2.69
+US$0.03 · +1.13%
盤前
US$2.68
−US$0.01 · -0.37%
10月12日 上午5:07 ET
盤中時間採用ET。市場資料可能有所延遲。
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
日內區間
目前US$2.69
52週區間
目前US$2.69
盤中時間採用ET。市場資料可能有所延遲。
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
日內區間
目前US$2.69
52週區間
目前US$2.69
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.29億 USD | 9959.7萬 USD | 8357萬 USD | 7205萬 USD | 6744.9萬 USD |
| 銷貨成本 | 4623.4萬 USD | 3801.1萬 USD | 3279萬 USD | 2925.3萬 USD | 2595.9萬 USD |
| 毛利 | 8318.9萬 USD | 6158.6萬 USD | 5078萬 USD | 4279.7萬 USD | 4149萬 USD |
| 研究與開發 | 633萬 USD | 601.6萬 USD | 495.8萬 USD | 482.6萬 USD | 383.2萬 USD |
| 銷售、一般及管理費用 | 6256.3萬 USD | 4784.4萬 USD | 5142.1萬 USD | 5659.9萬 USD | 6473.1萬 USD |
| 營業費用 | 6889.3萬 USD | 5386萬 USD | 5637.9萬 USD | 6142.5萬 USD | 6856.3萬 USD |
| 利息收入 | 212.7萬 USD | 112.9萬 USD | 66.1萬 USD | 3000 USD | — |
| 利息支出 | — | — | — | — | 5.5萬 USD |
| 折舊和攤銷 | 145萬 USD | 148.4萬 USD | 170.5萬 USD | 188.4萬 USD | 162.6萬 USD |
| 營業利益 | 1429.6萬 USD | 772.6萬 USD | −559.9萬 USD | −1862.8萬 USD | −2707.3萬 USD |
| 淨利 | 1738.2萬 USD | 855萬 USD | −493.8萬 USD | −1654萬 USD | −2712.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$10.33
上漲空間 284.01%AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。